Table 2.
Health state | VAS value (n = 200) Mean (SD) |
TTO value (n = 200) Mean (SD) |
---|---|---|
Base State 1 (receiving ADT) | 49.4 (19.1) | 0.71 (0.26) |
Base State 2 (receiving docetaxel + ADT) | 42.4 (18.0) | 0.64 (0.27) |
Base State 3 (completed docetaxel + on ADT; not progressed) | 46.0 (18.5) | 0.68 (0.26) |
AEs (Base State 2 + specific AE) | ||
Fatigue | 34.9 (16.8) | 0.54 (0.34) |
Nausea and vomiting | 26.6 (15.4) | 0.41 (0.36) |
Reduced immunity | 30.9 (15.8) | 0.48 (0.33) |
Fluid retention | 36.7 (16.4) | 0.58 (0.29) |
Alopecia | 33.4 (18.7) | 0.58 (0.29) |
Diarrhoea | 25.6 (15.8) | 0.40 (0.38) |
Dead | 3.9 (7.1) |
VAS values from 0 (“worst health”) to 100 (“best health”); TTO values from 0 (“equivalent to being dead”) to 1 (“perfect health”); a negative value would indicate a state worse than being dead
ADT androgen deprivation therapy, AE adverse event, n number, SD standard deviation, TTO time trade-off, VAS visual analogue scale